User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8086

Interactions with Platform & by Email *

INTERACTIONS

1132

Unique # Participated *

PARTICIPANTS

243

Responses Validated *

VALIDATIONS

46

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Chemotherapy Drugs.....I-3
Targeted Drugs.....I-3
  
   Lung Cancer Therapeutics – Driven by Next Generation Drugs.....II-1
New Therapies Drive NSCLC Market.....II-1
1$100
   Market Value of Taxanes to Decrease by 2015.....II-2
Lung Cancer – The Killer Disease.....II-2
1$100
   Lung Cancer – A Quick Glance at Global Statistics.....II-31$100
   Asia Heading for Possible Lung Cancer Epidemic.....II-4
Table 1: Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart).....II-4
1$300
   Lungs – Critical for Oxygen Supply.....II-5
Lung Cancer – An Introduction.....II-5
Common Symptoms of Lung Cancer.....II-5
1$100
   Types of Lung Cancer.....II-6
Non-Small Cell Lung Cancer.....II-6
NSCLC – At a Glance.....II-6
Small Cell Lung Cancer.....II-6
1$100
   Risk Factors for Lung Cancer.....II-7
Female Smokers at Higher Risk of Developing Lung Cancer.....II-7
Lung Cancer Diagnostics.....II-7
1$100
   Lung Cancer Staging.....II-81$100
   Staging for Non-Small Cell Lung Cancer.....II-9
Staging for Small Cell Lung Cancer.....II-9
1$100
   Surgery .....II-10
Radiation Therapy.....II-10
Chemotherapy.....II-10
Combination Therapy.....II-10
1$100
   Photodynamic Therapy.....II-11
Vaccines.....II-11
Common Treatment Modalities for SCLC and NSCLC Lung Cancers.....II-11
Pain Management.....II-11
1$100
   Chemotherapy.....II-12
Drug Administration.....II-12
Overview of Chemotherapy Regimens and Drugs.....II-12
1$100
   Side Effects of Chemotherapy.....II-13
Targeted Therapy.....II-13
Chemotherapy Drugs for SCLC Treatment.....II-13
1$100
   Chemotherapy Drugs for NSCLC Treatment.....II-14
Major Chemotherapy Drugs.....II-14
Select Chemotherapy Drugs Used in the Treatment of Lung Cancer by Brand and Generic
  Name.....II-14
1$100
   Overview of Select Chemotherapeutic Drugs.....II-15
Alimta.....II-15
Carboplatin and Cisplatin.....II-15
1$100
   Docetaxel.....II-16
Paclitaxel.....II-16
1$100
   Xyotax.....II-17
Gemcitabine.....II-17
Gefitinib.....II-17
1$100
   Irinotecan.....II-18
Vinorelbine (Navelbine®).....II-18
1$100
   R&D Focus in NSCLC Treatment.....II-19
Drug Development Process – Growth Opportunities & Challenges.....II-19
1$100
   Product Pipeline for NSCLC Treatment.....II-20
Product Pipeline for NSCLC Treatment.....II-20
1$100
   Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment.....II-211$100
   Companies Focus on Molecular Targeted Therapies.....II-22
Molecular Targeted Therapies – Overview of Select Product Candidates.....II-22
Aflibercept (VEGF-Trap) – Sanofi Aventis/ Regeneron.....II-22
BIBW 2992 – Boehringer Ingelheim.....II-22
Erbitux (cetuximab) - ImClone/Merck Serono/Bristol- Myers Squibb.....II-22
1$100
   Nexavar (sorafenib) - Bayer Schering.....II-23
Recentin (cediranib) – AstraZeneca.....II-23
Sutent (sunitinib) – Pfizer.....II-23
Zactima (vandetanib) – AstraZeneca.....II-23
Zolinza (vorinostat) – Merck & Co.....II-23
1$100
   Pipeline for Cytotoxic Therapy – Overview of Select Products.....II-24
Abraxane (albumin-bound paclitaxel) - Abraxis.....II-24
Glutoxim (NOV-002) - Novelos.....II-24
Javlor (vinflunine) – Pierre Fabre.....II-24
Lipoplatin (liposomal cisplatin) – Regulon.....II-24
Xyotax (paclitaxel polyglumex) - Cell Therapeutics/ Novartis.....II-24
1$100
   Intas Biopharmaceuticals to Introduce Gefitinib in India.....II-25
Celgene Receives FDA Fast Track Product Designation for Amrubicin.....II-25
EMEA Approves ALIMTA for First-Line Therapy of Advanced NSCLC.....II-25
Celgene’s Cancer Drug Receives Orphan Drug Status from European Commission.....II-25
1$100
   Alimta Receives FDA Approval.....II-26
Roche Receives Approval from European Authorities for Avastin.....II-26
OSI Pharmaceuticals Introduces Tarceva in Japan.....II-26
Shanghai Medipharm Introduces TNT Antibody for Treating Lung Cancer.....II-26
Natco Pharma Unveils an Injectible Drug for Lung Cancer, Pemnat.....II-26
1$100
   Roche Scientific Introduces Tarceva in the Indian Market.....II-27
GlaxoSmithKline’s HYCAMTIN® Receives Marketing Approval from EC.....II-27
Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer Treatment.....II-27
1$100
   UT Southwestern Medical Center Researchers Discover New Anti-Cancer Drug.....II-28
Agennix's Talactoferrin Alfa Program Obtains Fast Track Designation from FDA.....II-28
Novelos Therapeutics’ NOV-002 Receives Fast Track Designation from FDA.....II-28
1$100
   Novartis Commences Phase III Clinical Trial of ASA404.....II-29
Results of BR.21 Trials.....II-29
Genentech Announces Results of Phase III BETA Lung Trial.....II-29
Results of SATURN Clinical Trial.....II-29
1$100
   Results of Zactima’s Clinical Trials.....II-30
Results of Erbitux’s Phase III Trials.....II-30
Results of Roche’s AVAiL Clinical Trial.....II-30
1$100
   GlaxoSmithKline Conducts Phase III Clinical Trial of Lung Cancer Vaccine.....II-31
FASgen Announces Research Results of FAS093.....II-31
The Cuban Regulatory Agency Registers a New Therapeutic Lung Cancer Vaccine.....II-31
1$100
   Gemin X Commences Clinical Trials of GX15-070.....II-32
Antisoma and Biomira Announce Clinical Trial Results of Lung Cancer Drugs.....II-32
1$100
   OSI Pharmaceuticals Commences Phase III Clinical Trials of Tarceva®.....II-33
Northwest Gets FDA Clearance to Conduct Clinical Trials for Lung Cancer
  Vaccine.....II-33
University of Kentucky Conducts Clinical Trials on Lung Cancer Vaccine.....II-33
1$100
   Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical Trials of
  Picoplatin.....II-34
Sunesis Pharmaceuticals Starts Phase II Clinical Trials of SNS-595.....II-34
1$100
   Ligand Pharmaceuticals Tables Clinical Results of Targretin®.....II-35
Bayer and Onyx Start Phase III Trial of Nexavar®.....II-35
Abraxis Announces Clinical Results of ABRAXANE®.....II-35
Introgen Conducts Phase II Clinical Trials of INGN 225.....II-35
1$100
   YM BioSciences Commences Clinical Trial of Nimotuzumab.....II-36
1$100
   Merck Agrees to Merge with Shering-Plough.....II-37
Abbott Molecular Signs Agreement with Genentech, OSI and Roche.....II-37
IMUC Acquires Monoclonal Antibody Technology from MDC.....II-37
Quest PharmaTech Enters into Collaboration with BC Cancer Agency.....II-37
1$100
   Daiichi Sankyo Acquires U3 Pharma.....II-38
MacroGenics Takes Over Raven Biotechnologies.....II-38
Roche Acquires Piramed.....II-38
1$100
   Bristol-Myers Squibb Acquires Kosan Biosciences.....II-39
Point Therapeutics and DARA Biosciences Ink Merger Agreement.....II-39
Celgene Acquires Pharmion.....II-39
Pfizer to Takeover Serenex.....II-39
ATS Acquires Majority Stake in GANYMED Pharmaceuticals.....II-39
1$100
   NCCN, AstraZeneca and Abraxis Enter into Collaboration.....II-40
Eli Lilly Agrees to Take Over ImClone Systems.....II-40
CytRx Takes Over Innovive Pharmaceuticals.....II-40
1$100
   Abbott Extends Discovery Partnership with Caprion.....II-41
Bristol-Myers and ImClone to Expand the Clinical Development Program for
  ERBITUX.....II-41
1$100
   Biomoda and New Mexico Tech Enter into a Collaborative Agreement.....II-42
Binex Inks Sponsored Research Agreement with MaxCyte.....II-42
Simcere Pharmaceutical Acquires Master Luck.....II-42
Dako Enters into Collaboration with OSI, Roche, and Genentech.....II-42
1$100
   Biomira and Merck Sign Revised Supply and Collaboration Agreements.....II-43
ImClone Systems Terminates Development Agreement with UCB.....II-43
Astellas Pharma’s US Subsidiary Acquires Agensys.....II-43
1$100
   Antisoma Enters into an Agreement with Novartis.....II-44
Pharmacyclics Files NDA for Xcytrin® Injection.....II-44
1$100
   AstraZeneca PLC (UK).....II-45
Bristol-Myers Squibb Co. (US).....II-45
Eli Lilly & Co. (US).....II-45
F. Hoffmann-La Roche Ltd (Switzerland).....II-45
1$100
   Genentech, Inc. (US).....II-46
GlaxoSmithKline Plc (UK).....II-46
Novartis Pharmaceuticals Corporation (US).....II-46
OSI Pharmaceuticals, Inc. (US).....II-46
Sanofi-Aventis (France).....II-46
1$100
   Companies with Pipeline Drugs.....II-47
AbGenomics International Inc. (US).....II-47
ImClone Systems, Inc. (US).....II-47
Pfizer, Inc. (US).....II-47
Merck Serono International S.A. (Switzerland).....II-47
Merck & Co. Ltd. (US).....II-47
1$100
   Telik, Inc. (US).....II-48
Woomera Therapeutics, Inc. (US).....II-48
1$100
   Table 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – US, Europe and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....II-491$300
   Table 3: World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – Percentage Breakdown of Annual Revenues for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-501$300
   A. Market Analysis.....III-1
NSCLC Drug Market to Rise Sharply.....III-1
Lung Cancer Prevalence.....III-1
A Major Cause of Death among US Women.....III-1
1$75
   Statistics.....III-21$75
   Market Scenario.....III-3
FDA Places New Restrictions on Iressa.....III-3
Innovative Technology Enables Early Diagnosis of Lung Cancer.....III-3
Avastin to Emerge as the Preferred NSCLC Drug in the US.....III-3
1$75
   Product Approvals/Clinical Trials/Introductions/ Launches.....III-43$225
   Strategic Corporate Developments.....III-76$450
   Key Players.....III-133$225
   B. Market Analytics.....III-16
Table 4: US Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Segment – Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-16

Table 5: US 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Segment – Percentage Breakdown of Annual Revenues for Chemotherapy Drugs and Targeted Drugs Markets for Years 2006, 2009 & 2015.....III-16
1$150
   A. Market Analysis.....III-17
Lung Cancer Therapeutics Market to Witness Robust Growth.....III-17
Product Approvals.....III-17
2$150
   Clinical Trials.....III-19
B. Market Analytics.....III-19
Table 6: European Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-19
1$150
   Table 7: European 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-20
1$150
   A. Market Analysis.....III-21
Overview of Lung Cancer Market.....III-21
Key Player.....III-21
1$75
   B. Market Analytics.....III-22
Table 8: French Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-22
1$150
   A. Market Analysis.....III-23
Lung Cancer Scenario.....III-23
Chemotherapy Gains Preference.....III-23
1$75
   Strategic Corporate Developments.....III-241$75
   B. Market Analytics.....III-25
Table 9: German Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-25
1$150
   A. Market Analysis.....III-26
Incidence in Women on Rise.....III-26
Treatment.....III-26
B. Market Analytics.....III-26
Table 10: Italian Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-26
1$150
   A. Market Analysis.....III-27
British Women at Higher Risk.....III-27
Fast Facts.....III-27
Proposed Cancer Care Improvements Mulled by British Government.....III-27
1$75
   NICE Recommends Use of Erlotinib in NSCLC Treatment.....III-28
Strategic Corporate Developments.....III-28
1$75
   Key Players.....III-29
B. Market Analytics.....III-29
Table 11: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-29
1$150
   A. Market Analysis.....III-30
Outlook.....III-30
Strategic Corporate Developments.....III-30
Key Player.....III-30
1$75
   B. Market Analytics.....III-31
Table 12: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-31
1$150
   A. Market Analysis.....III-32
Australia.....III-32
Fast Facts.....III-32
Brazil.....III-32
China.....III-32
Overview of NSCLC Drug Market.....III-32
1$75
   India.....III-33
Japan.....III-33
Product Launches.....III-33
2$150
   Strategic Corporate Development.....III-351$75
   B. Market Analytics.....III-36
Table 13: Rest of World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-36
1$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com